NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: AAREYDRUGS · data 2026-11-01
Aarey Drugs & Pharmaceuticals Ltd.
In plain words
Price: 7.4% below its 52-week high of ₹114.8.
Delivery: 67.7% of traded shares were kept for delivery over the last 10 sessions, against 64.2% over the last 60.
Latest results: a net profit of ₹1 cr for the quarter ended Jun 2026 (-25.5% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹415 cr |
| Net profit (last 12 months) | ₹4 cr |
| Sales growth, 3 years (yearly) | 4.1% |
| Profit growth, 3 years (yearly) | 1.7% |
At a glance
Promoters 41.5% (-3.3 pts in a year), pledged 0.0%, institutions 5.7%.
P/E 72.4, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 2.7%, ROCE 6.0%, operating margin 0.9%: how much profit it earns on the money it uses.
Debt/equity 0.33, Profit growth 1.7% and sales growth 4.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (2.7%).
- Thin operating margin (0.9%).
- Slow sales growth (4.1% a year over 3 years).
- Promoters cut their holding by 3.3 points in a year.
- Expensive on earnings (P/E 72.4).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
AAREYDRUGS Q1 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹44.63 crore, down 56.3% YoY and down 76.4% QoQ.
Net profit was ₹1.02 crore, down 25.5% YoY and down 34.6% QoQ.
Operating margin was 3% (1.7% a year ago).
EPS was ₹0.36, down 25% YoY and down 34.5% QoQ.
AAREYDRUGS के Q1 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹44.63 करोड़; पिछले साल की तुलना में 56.3% की गिरावट, पिछली तिमाही की तुलना में 76.4% की गिरावट।
शुद्ध मुनाफ़ा: ₹1.02 करोड़; पिछले साल की तुलना में 25.5% की गिरावट, पिछली तिमाही की तुलना में 34.6% की गिरावट।
ऑपरेटिंग मार्जिन: 3% (एक साल पहले 1.7%)।
EPS: ₹0.36; पिछले साल की तुलना में 25% की गिरावट, पिछली तिमाही की तुलना में 34.5% की गिरावट।
AAREYDRUGSના Q1 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹44.63 કરોડ; ગયા વર્ષની સરખામણીએ 56.3% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 76.4% ઘટાડો.
ચોખ્ખો નફો: ₹1.02 કરોડ; ગયા વર્ષની સરખામણીએ 25.5% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 34.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 3% (એક વર્ષ પહેલાં 1.7%).
EPS: ₹0.36; ગયા વર્ષની સરખામણીએ 25% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 34.5% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
38/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 13/30: Delivery 66.5% over the last 20 sessions vs 53.8% in the 40 before (1.24x); shares delivered per day 1.21x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 14/20: Net +₹1.44 cr bought in bulk/block deals over 90 days (0.58x a usual day's traded value); 1 net buying day, 0 net selling days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Deal ● Results
- 23 Oct 26Insider SAST disclosure: Nimit Rajesh Ghatalia acquired 1,50,000 shares -6.5% next session
- 7 Oct 26Deal Bulk deal: VAYUMIND INNOVATIONS PRIVATE LIMITED bought ₹1.97 cr (net ₹0 cr) -3.7% next session
- 30 Sept 26Deal Bulk deal: ARYA RAVI MANIRAM bought ₹1.44 cr +3.9% next session
- 14 Aug 26Results Q1 FY27 results: profit −25.5% YoY +1.3% next session
- 30 May 26Results Q4 FY26 results: profit +231.9% YoY -0.8% next session
- 11 Apr 26Results Q3 FY26 results: profit −20.8% YoY +4.8% next session
- 14 Nov 25Results Q2 FY26 results: profit −36.3% YoY +0.1% next session
- 13 Aug 25Results Q1 FY26 results: profit +10.5% YoY 0.0% next session
- 31 May 25Results Q4 FY25 results: profit −78.1% YoY -4.3% next session
- 14 Feb 25Results Q3 FY25 results: profit −29.4% YoY -6.2% next session
- 14 Nov 24Results Q2 FY25 results: profit +105.1% YoY -4.5% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹45 cr | ₹1 cr | -25.5% | 3.0% | 0.36 |
| Mar 2026 | ₹189 cr | ₹2 cr | +231.9% | 2.3% | 0.55 |
| Dec 2025 | ₹96 cr | ₹1 cr | -20.8% | -1.6% | 0.2 |
| Sept 2025 | ₹84 cr | ₹1 cr | -36.3% | 3.1% | 0.72 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 41.45% | 37.71% | 37.71% | 39.06% |
| Foreign institutions (FII) | 4.27% | 4.80% | 4.18% | 3.86% |
| Domestic institutions (DII) | 1.44% | 1.62% | 1.62% | — |
| Mutual funds | — | — | — | — |
| Retail investors | 13.83% | 15.54% | 16.69% | 16.85% |
| Number of shareholders | 13,485 | 13,478 | 14,188 | 14,063 |
Common questions
What was Aarey Drugs & Pharmaceuticals Ltd.'s latest quarterly profit?
Aarey Drugs & Pharmaceuticals Ltd. reported a net profit of ₹1 cr for the quarter ended Jun 2026 (-25.5% on the same quarter a year earlier), on revenue of ₹45 cr.
How much do promoters hold in Aarey Drugs & Pharmaceuticals Ltd.?
Promoters held 41.45% of Aarey Drugs & Pharmaceuticals Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Aarey Drugs & Pharmaceuticals Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.33.
What is Aarey Drugs & Pharmaceuticals Ltd.'s P/E ratio?
About 72.4, based on the last 12 months' earnings and a price of ₹106.26 (data 2026-11-01).
What is the 52-week high and low of Aarey Drugs & Pharmaceuticals Ltd.?
The 52-week high is ₹114.8 and the 52-week low is ₹50.31.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Aarey Drugs & Pharmaceuticals Ltd. | ₹106.26 | ₹298 cr | 72.4 | — | 2.7% | 6% | 0.33 | +15.4% |
| Albert David Ltd | ₹762.8 | ₹435 cr | 19.3 | — | -0.4% | 0.3% | 0.08 | -11.0% |
| Jenburkt Pharmaceuticals Ltd | ₹853.6 | ₹377 cr | 11.5 | — | 18.8% | 22.7% | 0.01 | -18.1% |
| Medicamen Biotech Limited | ₹256.2 | ₹347 cr | 31.3 | — | 3.9% | 5.5% | 0.18 | -27.6% |
| Ambalal Sarabhai Enterprises Limited | ₹34.99 | ₹268 cr | 19.8 | — | 11.9% | 9.4% | 0.36 | +8.3% |
| Accretion Pharmaceuticals Ltd. | ₹190.05 | ₹211 cr | 21.9 | 3.9 | 27.6% | 38.3% | 0.23 | +234.9% |
Compare AAREYDRUGS with ALBERTDAVD in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AAREYDRUGS in NSE Scanner →